Moderna’s Covid-19 Vaccine May Reach Some by as Soon as Fall (1)

March 23, 2020, 2:19 PM

Moderna Inc. said its experimental vaccine for Covid-19 could be available to a select few as soon as this fall, ahead of expectations for a commercial release in a year.

Stephane Bancel, the biotech’s chief executive, told Goldman Sachs on Friday that mRNA-1273 could be made available to a few, potentially health-care workers, under emergency use authorization, according to a company statement. The vaccine was developed in partnership with Moderna and the National Institute of Allergy and Infectious Diseases. Human testing started earlier this month.

A potential vaccine is not expected to be commercially available for at least a year. Moderna is also scaling up manufacturing capacity so it can produce millions of doses each month, the company said.

Moderna’s stock rose as much as 2.7% on Monday after a volatile Friday as investors reflected on the 12-month or longer time frame for a new treatment for the virus.

(Updates to add share move, chart)

To contact the reporter on this story:
Cristin Flanagan in New York at cflanagan1@bloomberg.net

To contact the editors responsible for this story:
Catherine Larkin at clarkin4@bloomberg.net

Richard Richtmyer

© 2020 Bloomberg L.P. All rights reserved. Used with permission.

To read more articles log in.

Learn more about a Bloomberg Law subscription.